Hepatitis B vaccination uptake and correlates of serologic response among HIV-infected and uninfected men who have sex with men (MSM) in Bangkok, Thailand
| Autor: | Sarika Pattanasin, Janet M. McNicholl, Timothy H. Holtz, Jaray Tongtoyai, Punneeporn Wasinrapee, Wannee Chonwattana, Boonyos Raengsakulrach, Supaporn Chaikummao, Marcel E. Curlin, Frits van Griensven |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Hepatitis B vaccine Adolescent 030106 microbiology HIV Infections medicine.disease_cause Men who have sex with men Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine HIV Seropositivity medicine Humans Hepatitis B Vaccines 030212 general & internal medicine Hepatitis B Antibodies Homosexuality Male Hepatitis B virus General Veterinary General Immunology and Microbiology Coinfection business.industry Public Health Environmental and Occupational Health virus diseases Middle Aged Viral Load Hepatitis B Thailand medicine.disease CD4 Lymphocyte Count Immunity Humoral Vaccination Infectious Diseases Immunoglobulin G Immunology Molecular Medicine business Viral load Vaccine failure |
| Zdroj: | Vaccine. 34:2044-2050 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2015.11.071 |
| Popis: | Vaccination against hepatitis B virus (HBV) is recommended for all HBV-susceptible men who have sex with men (MSM). There is limited information on correlates of immunity to HBV vaccination in this group. We present serologic response rates to hepatitis B vaccine and identify factors associated with impaired response among HIV-uninfected and HIV-infected Thai MSM.HBV-susceptible volunteers were offered hepatitis B vaccination at months zero, one, and six. We measured baseline (pre-vaccination) total serum IgG and IgG subclasses (all participants), baseline CD4 count, and plasma HIV-1 viral load (PVL) (HIV+ participants). HBV serologies were retested at 12 months. Serologic responses were compared between all groups in men receiving three vaccine doses.511/651 HIV-negative and 64/84 HIV-positive participants completed the three-dose series. Response rates in HIV-uninfected and -infected participants were 90.1% vs. 50.0% (p0.0001). Median pre-vaccination IgG was higher among non-responders than responders overall (1238.9.0 vs. 1057.0mg/dL, p=0.003) and among HIV-infected participants (1534.0 vs. 1244.5mg/dL, p=0.005), but not significantly among HIV-uninfected participants (1105.5 vs. 1054.3mg/dL, p=0.96). Pre-vaccination IgG1 and IgG3 levels were higher among HIV-positive than HIV-negative participants (median 866.0 vs. 520.3, and 105.8 vs. 83.1mg/dL, respectively, p0.0001). Among HIV-infected participants, median CD4 count in non-responders was 378 cells/μL vs. 431 cells/μL in responders (p=0.20). Median PVL in non-responders was 64,800 copies/mL vs. 15500 copies/mL in responders (p=0.04). Participants with pre-vaccination plasma IgG1550 mg/dL and PVL10,000 copies/mL were almost always non-responsive (p0.01).HIV infection was associated with poor vaccine responses. High plasma viral load, elevated pre-vaccination total serum IgG and elevated pre-vaccination IgG1 are associated with poorer response to vaccination among HIV-infected MSM. In this group, the combination of high PVL and pre-vaccination total IgG is highly predictive of vaccine failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect